{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:05:19Z","timestamp":1784016319586,"version":"3.55.0"},"reference-count":240,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.nano.2026.102965","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:49:28Z","timestamp":1780292968000},"page":"102965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advances in nanomedicine for ocular inflammatory diseases"],"prefix":"10.1016","volume":"75","author":[{"given":"Demeng","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.nano.2026.102965_bb0005","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1038\/s41433-024-02966-w","article-title":"Infectious eye disease in the 21st century\u2014an overview","volume":"38","author":"Clare","year":"2024","journal-title":"Eye"},{"issue":"11","key":"10.1016\/j.nano.2026.102965_bb0010","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1007\/s12274-020-2980-9","article-title":"iRGD decorated liposomes: a novel actively penetrating topical ocular drug delivery strategy","volume":"13","author":"Huang","year":"2020","journal-title":"Nano Res"},{"issue":"7","key":"10.1016\/j.nano.2026.102965_bb0015","article-title":"A comprehensive review of ocular manifestations in systemic diseases","volume":"16","author":"Kumar","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.nano.2026.102965_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1267091","article-title":"The role of inflammation in autoimmune disease: a therapeutic target","volume":"14","author":"Xiang","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.nano.2026.102965_bb0025","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.mpaic.2024.04.003","article-title":"Immune response to infection","volume":"25","author":"Cumming","year":"2024","journal-title":"Anaesth Intens Care Med"},{"issue":"3","key":"10.1016\/j.nano.2026.102965_bb0030","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/15321819.2020.1726774","article-title":"Biomarkers of inflammation and oxidative stress in ophthalmic disorders","volume":"41","author":"Ahmad","year":"2020","journal-title":"J Immunoass Immunochem"},{"key":"10.1016\/j.nano.2026.102965_bb0035","series-title":"Grand Challenges in Ocular Inflammatory Diseases","first-page":"756689","author":"Xu","year":"2022"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0040","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12951-023-01974-4","article-title":"Next-generation nanomaterials: advancing ocular anti-inflammatory drug therapy","volume":"21","author":"Wei","year":"2023","journal-title":"J Nanobiotechnol"},{"issue":"3","key":"10.1016\/j.nano.2026.102965_bb0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1208\/s12249-021-01977-0","article-title":"Review of approaches for increasing ophthalmic bioavailability for eye drop formulations","volume":"22","author":"Lanier","year":"2021","journal-title":"AAPS PharmSciTech"},{"issue":"7","key":"10.1016\/j.nano.2026.102965_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071862","article-title":"Innovative strategies for drug delivery to the ocular posterior segment","volume":"15","author":"Gabai","year":"2023","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.nano.2026.102965_bb0055","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1177\/24741264211028441","article-title":"Intravitreal injection therapy: current techniques and supplemental services","volume":"5","author":"Lam","year":"2021","journal-title":"J VitreoRet Dis"},{"issue":"6","key":"10.1016\/j.nano.2026.102965_bb0060","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.3390\/pharmaceutics15061646","article-title":"Corneal permeability and uptake of twenty-five drugs: species comparison and quantitative structure\u2013permeability relationships","volume":"15","author":"Santana","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.102965_bb0065","doi-asserted-by":"crossref","first-page":"815075","DOI":"10.3389\/fmed.2021.815075","article-title":"Current advances in mechanisms and treatment of dry eye disease: toward anti-inflammatory and immunomodulatory therapy and traditional Chinese medicine","volume":"8","author":"Ling","year":"2022","journal-title":"Front Med"},{"issue":"26","key":"10.1016\/j.nano.2026.102965_bb0070","doi-asserted-by":"crossref","first-page":"2302174","DOI":"10.1002\/advs.202302174","article-title":"Poly (l-histidine)-mediated on-demand therapeutic delivery of roughened ceria nanocages for treatment of chemical eye injury","volume":"10","author":"Yang","year":"2023","journal-title":"Adv Sci"},{"issue":"2","key":"10.1016\/j.nano.2026.102965_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/gels8020082","article-title":"Drug delivery challenges and current progress in nanocarrier-based ocular therapeutic system","volume":"8","author":"Akhter","year":"2022","journal-title":"Gels"},{"issue":"20","key":"10.1016\/j.nano.2026.102965_bb0080","doi-asserted-by":"crossref","first-page":"15352","DOI":"10.3390\/ijms242015352","article-title":"Overview of recent advances in nano-based ocular drug delivery","volume":"24","author":"Liu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.nano.2026.102965_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/ph16030454","article-title":"Properties of poly (lactic-co-glycolic acid) and progress of poly (lactic-co-glycolic acid)-based biodegradable materials in biomedical research","volume":"16","author":"Lu","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"4","key":"10.1016\/j.nano.2026.102965_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13040447","article-title":"Lipid-based nanocarriers for ophthalmic administration: towards experimental design implementation","volume":"13","author":"Gonzalez-Fernandez","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.102965_bb0095","article-title":"Nanomedicine in glaucoma treatment; current challenges and future perspectives","volume":"28","author":"Iqbal","year":"2024","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.nano.2026.102965_bb0100","doi-asserted-by":"crossref","first-page":"1260592","DOI":"10.3389\/fimmu.2023.1260592","article-title":"Effects of inflammation on myopia: evidence and potential mechanisms","volume":"14","author":"Xu","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.nano.2026.102965_bb0105","doi-asserted-by":"crossref","first-page":"001978","DOI":"10.1099\/jmm.0.001978","article-title":"Impact of cyclosporine a on the progression of ocular surface diseases: treatment efficacy and potential complications","volume":"74","author":"Begimbayeva","year":"2025","journal-title":"J Med Microbiol"},{"issue":"7","key":"10.1016\/j.nano.2026.102965_bb0110","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3390\/v16071110","article-title":"Overview of cytomegalovirus ocular diseases: retinitis, corneal endotheliitis, and iridocyclitis","volume":"16","author":"Kobayashi","year":"2024","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.nano.2026.102965_bb0115","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jama.2025.4358","article-title":"Uveitis in adults: a review","volume":"334","author":"Maghsoudlou","year":"2025","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.nano.2026.102965_bb0120","first-page":"882","article-title":"Etiology and anatomical location of uveitis\u2014prognostic factors for disease course and laterality","volume":"15","author":"Mitkova-Hristova","year":"2025","journal-title":"Life (Basel)"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0125","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12951-024-02448-x","article-title":"Mucoadhesive, antioxidant, and lubricant catechol-functionalized poly(phosphobetaine) as biomaterial nanotherapeutics for treating ocular dryness","volume":"22","author":"Bui","year":"2024","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0130","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12348-023-00342-5","article-title":"Challenges in posterior uveitis\u2014tips and tricks for the retina specialist","volume":"13","author":"Paez-Escamilla","year":"2023","journal-title":"J Ophthalmol Inflamm Infect"},{"key":"10.1016\/j.nano.2026.102965_bb0135","series-title":"Radiology of Infectious and Inflammatory Diseases\u2014Volume 2: Head and Neck","first-page":"93","article-title":"Eyeball lesions","author":"Zheng","year":"2022"},{"issue":"2","key":"10.1016\/j.nano.2026.102965_bb0140","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcjo.2024.07.013","article-title":"Anterior uveitis for the comprehensive ophthalmologist","volume":"60","author":"Xie","year":"2025","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.nano.2026.102965_bb0145","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.actbio.2022.01.044","article-title":"Alleviation of dry eye syndrome with one dose of antioxidant, anti-inflammatory, and mucoadhesive lysine-carbonized nanogels","volume":"141","author":"Lin","year":"2022","journal-title":"Acta Biomater"},{"issue":"3","key":"10.1016\/j.nano.2026.102965_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/immuno5030024","article-title":"Sj\u00f6gren\u2019s syndrome and ocular inflammation: pathophysiology, clinical manifestation and mitigation strategies","volume":"5","author":"Pavlidis","year":"2025","journal-title":"Immuno"},{"key":"10.1016\/j.nano.2026.102965_bb0155","series-title":"Antimicrobial Resistance of the Human Eye","first-page":"314","article-title":"Antimicrobial resistance in the diseased human eye: scleritis","author":"Shivaji","year":"2024"},{"issue":"24","key":"10.1016\/j.nano.2026.102965_bb0160","doi-asserted-by":"crossref","first-page":"25118","DOI":"10.1021\/acsnano.3c07817","article-title":"Unveiling the power of gabapentin-loaded nanoceria with multiple therapeutic capabilities for the treatment of dry eye disease","volume":"17","author":"Yang","year":"2023","journal-title":"ACS Nano"},{"issue":"5","key":"10.1016\/j.nano.2026.102965_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms12050984","article-title":"Antibiotic resistance profiles in eye infections: a local concern with a retrospective focus on a large hospital in Northern Italy","volume":"12","author":"Drago","year":"2024","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0170","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1474-4422(22)00187-9","article-title":"Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment","volume":"22","author":"Bennett","year":"2023","journal-title":"Lancet Neurol"},{"issue":"15","key":"10.1016\/j.nano.2026.102965_bb0175","first-page":"2003699","article-title":"Ocular nanomedicine. advanced","volume":"9","author":"Tang","year":"2022","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.nano.2026.102965_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/ph15050547","article-title":"Therapeutic targets in allergic conjunctivitis","volume":"15","author":"Labib","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"10.1016\/j.nano.2026.102965_bb0185","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/APO.0000000000000341","article-title":"Current approach for the diagnosis and management of noninfective scleritis","volume":"10","author":"Majumder","year":"2021","journal-title":"Asia Pac J Ophthalmol"},{"key":"10.1016\/j.nano.2026.102965_bb0190","series-title":"Infectious Eye Diseases: Recent Advances in Diagnosis and Treatment","first-page":"3","article-title":"Infectious keratitis: update on diagnosis and therapy","author":"Alamillo-Velazquez","year":"2021"},{"key":"10.1016\/j.nano.2026.102965_bb0195","first-page":"22","article-title":"Recent advances in nanomedicine for ocular drug delivery","volume":"21","author":"Tung","year":"2025","journal-title":"Biomater Transl"},{"issue":"15","key":"10.1016\/j.nano.2026.102965_bb0200","doi-asserted-by":"crossref","first-page":"12090","DOI":"10.3390\/ijms241512090","article-title":"Ocular vascular diseases: from retinal immune privilege to inflammation","volume":"24","author":"Wang","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"23","key":"10.1016\/j.nano.2026.102965_bb0205","doi-asserted-by":"crossref","first-page":"14933","DOI":"10.3390\/ijms232314933","article-title":"Innate immune system activation, inflammation and corneal wound healing","volume":"23","author":"Fortingo","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0210","doi-asserted-by":"crossref","first-page":"2606928","DOI":"10.1155\/2022\/2606928","article-title":"Reactive oxygen species bridge the gap between chronic inflammation and tumor development","volume":"2022","author":"Yu","year":"2022","journal-title":"Oxidative Med Cell Longev"},{"issue":"12","key":"10.1016\/j.nano.2026.102965_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005973","article-title":"IL-1\u03b2\/IL-6\/CRP and IL-18\/ferritin: distinct inflammatory programs in infections","volume":"12","author":"Slaats","year":"2016","journal-title":"PLoS Pathog"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0220","first-page":"e70016","article-title":"Nanostructured drug delivery systems for posterior segment eye diseases: strategies to defy ocular barriers","volume":"4","author":"Shen","year":"2026","journal-title":"Biomed Eng Mater J"},{"issue":"7","key":"10.1016\/j.nano.2026.102965_bb0225","doi-asserted-by":"crossref","first-page":"6703","DOI":"10.1021\/acsnano.7b01023","article-title":"Super-cationic carbon quantum dots synthesized from spermidine as an eye drop formulation for topical treatment of bacterial keratitis","volume":"11","author":"Jian","year":"2017","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0230","doi-asserted-by":"crossref","first-page":"79","DOI":"10.52711\/2349-2988.2024.00013","article-title":"A review on ophthalmic drug delivery system","volume":"16","author":"Sanap","year":"2024","journal-title":"Res J Sci Technol"},{"key":"10.1016\/j.nano.2026.102965_bb0235","doi-asserted-by":"crossref","first-page":"119961","DOI":"10.1016\/j.biomaterials.2020.119961","article-title":"Dually functional hollow ceria nanoparticle platform for intraocular drug delivery: a push beyond the limits of static and dynamic ocular barriers toward glaucoma therapy","volume":"243","author":"Luo","year":"2020","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.nano.2026.102965_bb0240","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3390\/pharmaceutics17121504","article-title":"Emulsion and emulgel-based ophthalmic drug delivery systems","volume":"17","author":"Mohapatra","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.102965_bb0245","doi-asserted-by":"crossref","first-page":"126190","DOI":"10.1016\/j.cej.2020.126190","article-title":"Multifunctional glutathione-dependent hydrogel eye drops with enhanced drug bioavailability for glaucoma therapy","volume":"402","author":"Lai","year":"2020","journal-title":"Chem Eng J"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0250","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1021\/acsnano.2c05824","article-title":"Highly retina-permeating and long-acting resveratrol\/metformin nanotherapeutics for enhanced treatment of macular degeneration","volume":"17","author":"Nguyen","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.nano.2026.102965_bb0255","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jconrel.2023.01.018","article-title":"Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases","volume":"354","author":"Onugwu","year":"2023","journal-title":"J Control Release"},{"issue":"7","key":"10.1016\/j.nano.2026.102965_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071959","article-title":"Biomaterial drug delivery systems for prominent ocular diseases","volume":"15","author":"Sapowadia","year":"2023","journal-title":"Pharmaceutics"},{"issue":"44","key":"10.1016\/j.nano.2026.102965_bb0265","doi-asserted-by":"crossref","first-page":"6988","DOI":"10.1039\/D0PY00919A","article-title":"Advancing the stimuli response of polymer-based drug delivery systems for ocular disease treatment","volume":"11","author":"Nguyen","year":"2020","journal-title":"Polym Chem"},{"issue":"23","key":"10.1016\/j.nano.2026.102965_bb0270","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1111\/bph.14024","article-title":"Principles of pharmacology in the eye","volume":"174","author":"Awwad","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.nano.2026.102965_bb0275","doi-asserted-by":"crossref","first-page":"120924","DOI":"10.1016\/j.ijpharm.2021.120924","article-title":"Drug delivery to the anterior segment of the eye: a review of current and future treatment strategies","volume":"607","author":"Mofidfar","year":"2021","journal-title":"Int J Pharm"},{"issue":"suppl_1","key":"10.1016\/j.nano.2026.102965_bb0280","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1098\/rsif.2009.0285.focus","article-title":"Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases","volume":"7","author":"Ulbrich","year":"2010","journal-title":"J R Soc Interface"},{"key":"10.1016\/j.nano.2026.102965_bb0285","doi-asserted-by":"crossref","first-page":"114396","DOI":"10.1016\/j.jconrel.2025.114396","article-title":"Tiny tools, big vision: a minireview on carbonized nanomaterials in ophthalmology","author":"Unnikrishnan","year":"2025","journal-title":"J Control Release"},{"issue":"9","key":"10.1016\/j.nano.2026.102965_bb0290","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","article-title":"Polymeric nanoparticles for drug delivery","volume":"124","author":"Beach","year":"2024","journal-title":"Chem Rev"},{"issue":"6","key":"10.1016\/j.nano.2026.102965_bb0295","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11051-025-06363-6","article-title":"Innovative polymeric and non-polymeric nanocarrier systems for dexamethasone: enhancing precision and reducing side effects","volume":"27","author":"Pourmadadi","year":"2025","journal-title":"J Nanopart Res"},{"key":"10.1016\/j.nano.2026.102965_bb0300","doi-asserted-by":"crossref","first-page":"150199","DOI":"10.1016\/j.ijbiomac.2026.150199","article-title":"Marine-derived polysaccharides enhance the drug delivery mechanism in the management of ocular diseases: a review","author":"Anand","year":"2026","journal-title":"Int J Biol Macromol"},{"issue":"17","key":"10.1016\/j.nano.2026.102965_bb0305","doi-asserted-by":"crossref","first-page":"2304626","DOI":"10.1002\/adhm.202304626","article-title":"Recent advances in nanomedicine for ocular fundus neovascularization disease management","volume":"13","author":"Zhou","year":"2024","journal-title":"Adv Healthc Mater"},{"issue":"6","key":"10.1016\/j.nano.2026.102965_bb0310","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.3390\/app15063189","article-title":"Enhancement of EPR effect for passive tumor targeting: current status and future perspectives","volume":"15","author":"Vagena","year":"2025","journal-title":"Appl Sci (Basel)"},{"key":"10.1016\/j.nano.2026.102965_bb0315","doi-asserted-by":"crossref","first-page":"630352","DOI":"10.3389\/fbioe.2021.630352","article-title":"Update on nanoparticle-based drug delivery system for anti-inflammatory treatment","volume":"9","author":"Wang","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"issue":"5","key":"10.1016\/j.nano.2026.102965_bb0320","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41573-023-00670-0","article-title":"Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems","volume":"22","author":"Baryakova","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.nano.2026.102965_bb0325","doi-asserted-by":"crossref","first-page":"118337","DOI":"10.1016\/j.biopha.2025.118337","article-title":"Protein-functionalized nanoparticles: emerging strategies in drug delivery","volume":"189","author":"Wietrzyk","year":"2025","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"10.1016\/j.nano.2026.102965_bb0330","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3390\/nano10061191","article-title":"Niosomal drug delivery systems for ocular disease\u2014recent advances and future prospects","volume":"10","author":"Durak","year":"2020","journal-title":"Nanomaterials (Basel)"},{"issue":"7","key":"10.1016\/j.nano.2026.102965_bb0335","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1080\/17425247.2021.1872542","article-title":"Liposomes as vehicles for topical ophthalmic drug delivery and ocular surface protection","volume":"18","author":"Lopez-Cano","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0340","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.1038\/s41598-018-24545-2","article-title":"Evaluation of subconjunctival liposomal steroids for the treatment of experimental uveitis","volume":"8","author":"Wong","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.nano.2026.102965_bb0345","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.3390\/pharmaceutics15061593","article-title":"Solid lipid nanoparticles vs. nanostructured lipid carriers: a comparative review","volume":"15","author":"Viegas","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.102965_bb0350","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/S0169-409X(02)00118-7","article-title":"Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations","volume":"54","author":"M\u00fcller","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nano.2026.102965_bb0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cofs.2017.06.003","article-title":"Nanoemulsions: stability and physical properties","volume":"16","author":"de Oca-\u00c1valos","year":"2017","journal-title":"Curr Opin Food Sci"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0360","first-page":"6640103","article-title":"Nanoemulsion: an emerging novel technology for improving the bioavailability of drugs","volume":"2023","author":"Preeti","year":"2023","journal-title":"Scientifica (Cairo)"},{"issue":"24","key":"10.1016\/j.nano.2026.102965_bb0365","doi-asserted-by":"crossref","first-page":"1900702","DOI":"10.1002\/adhm.201900702","article-title":"Dendritic effects of injectable biodegradable thermogels on pharmacotherapy of inflammatory glaucoma-associated degradation of extracellular matrix","volume":"8","author":"Nguyen","year":"2019","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.nano.2026.102965_bb0370","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jconrel.2021.05.035","article-title":"Systemic dendrimer nanotherapies for targeted suppression of choroidal inflammation and neovascularization in age-related macular degeneration","volume":"335","author":"Kambhampati","year":"2021","journal-title":"J Control Release"},{"issue":"6","key":"10.1016\/j.nano.2026.102965_bb0375","article-title":"Gold nanoparticle: synthesis, functionalization, enhancement, drug delivery and therapy: a review","volume":"11","author":"Mohammed","year":"2020","journal-title":"Syst Rev Pharm"},{"key":"10.1016\/j.nano.2026.102965_bb0380","doi-asserted-by":"crossref","first-page":"rbac070","DOI":"10.1093\/rb\/rbac070","article-title":"Regenerative cerium oxide nanozymes alleviate oxidative stress for efficient dry eye disease treatment","volume":"9","author":"Zou","year":"2022","journal-title":"Regen Biomater"},{"key":"10.1016\/j.nano.2026.102965_bb0385","first-page":"101634","article-title":"Hollow nanoarchitectures: materials engineering, nanochemistry, and biomedical applications","author":"Ghosh","year":"2025","journal-title":"Prog Mater Sci"},{"key":"10.1016\/j.nano.2026.102965_bb0390","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.actbio.2025.12.016","article-title":"Engineered cerium oxide nanoparticles conjugated with carrier platforms: therapeutic mechanisms for skin wound healing applications","volume":"210","author":"Ger","year":"2025","journal-title":"Acta Biomater"},{"key":"10.1016\/j.nano.2026.102965_bb0395","doi-asserted-by":"crossref","first-page":"134970","DOI":"10.1016\/j.cej.2022.134970","article-title":"Synthesis, bioactive properties, and biomedical applications of intrinsically therapeutic nanoparticles for disease treatment","volume":"435","author":"Nguyen","year":"2022","journal-title":"Chem Eng J"},{"issue":"8","key":"10.1016\/j.nano.2026.102965_bb0400","article-title":"Advancing ocular medication delivery with nano-engineered solutions: a comprehensive review of innovations, obstacles, and clinical impact","volume":"16","author":"Rajan","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0405","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s43094-021-00331-2","article-title":"Recent advances in ocular drug delivery systems and targeting VEGF receptors for management of ocular angiogenesis: a comprehensive review","volume":"7","author":"Narayana","year":"2021","journal-title":"Future J Pharm Sci"},{"issue":"3","key":"10.1016\/j.nano.2026.102965_bb0410","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3390\/pharmaceutics14030533","article-title":"Lipid nanoparticles as a promising drug delivery carrier for topical ocular therapy\u2014an overview on recent advances","volume":"14","author":"Jacob","year":"2022","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.nano.2026.102965_bb0415","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3390\/ph16030474","article-title":"Recent progress of solid lipid nanoparticles and nanostructured lipid carriers as ocular drug delivery platforms","volume":"16","author":"Gugleva","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.nano.2026.102965_bb0420","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/187221050902150819151841","article-title":"Recent advances in ocular drug delivery, with special emphasis on lipid based nanocarriers","volume":"9","author":"Sah","year":"2015","journal-title":"Recent Pat Nanotechnol"},{"issue":"7","key":"10.1016\/j.nano.2026.102965_bb0425","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.3390\/pharmaceutics15072005","article-title":"Next-generation nanomedicine approaches for the management of retinal diseases","volume":"15","author":"Mahaling","year":"2023","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.nano.2026.102965_bb0430","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.3390\/pharmaceutics13101590","article-title":"Chitosan-coated PLGA nanoparticles encapsulating triamcinolone acetonide as a potential candidate for sustained ocular drug delivery","volume":"13","author":"Dandamudi","year":"2021","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.nano.2026.102965_bb0435","article-title":"A review on polymers in ocular drug delivery systems","volume":"3","author":"Bisen","year":"2024","journal-title":"MedComm Biomater Appl"},{"issue":"7","key":"10.1016\/j.nano.2026.102965_bb0440","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3390\/polym12071519","article-title":"Chitosan and its derivatives for ocular delivery formulations: recent advances and developments","volume":"12","author":"Zamboulis","year":"2020","journal-title":"Polymers (Basel)"},{"issue":"6","key":"10.1016\/j.nano.2026.102965_bb0445","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3390\/pharmaceutics15061591","article-title":"Dendrimers in corneal drug delivery: recent developments and translational opportunities","volume":"15","author":"Dhull","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.nano.2026.102965_bb0450","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3109\/10717544.2014.943336","article-title":"Liposomes in topical ophthalmic drug delivery: an update","volume":"23","author":"Agarwal","year":"2016","journal-title":"Drug Deliv"},{"key":"10.1016\/j.nano.2026.102965_bb0455","first-page":"0044","article-title":"Unraveling the therapeutic enigma of liposomes in ocular drug delivery","volume":"8","author":"Karmakar","year":"2025","journal-title":"J Bio-X Res"},{"issue":"4","key":"10.1016\/j.nano.2026.102965_bb0460","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ipha.2024.09.005","article-title":"Nanostructured lipid carriers as a drug delivery system: a comprehensive review with therapeutic applications","volume":"3","author":"Mall","year":"2024","journal-title":"Intelligent Pharmacy"},{"issue":"10","key":"10.1016\/j.nano.2026.102965_bb0465","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1021\/acs.molpharmaceut.1c00650","article-title":"Ophthalmic nanoemulsions: from composition to technological processes and quality control","volume":"18","author":"Gawin-Miko\u0142ajewicz","year":"2021","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0470","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.aopr.2024.01.008","article-title":"Recent progress of nanomedicine in managing dry eye disease","volume":"4","author":"Lv","year":"2024","journal-title":"Adv Ophthalmol Pract Res"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0475","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12951-023-01992-2","article-title":"Nanotechnology-based ocular drug delivery systems: recent advances and future prospects","volume":"21","author":"Li","year":"2023","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.nano.2026.102965_bb0480","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-025-03848-3","article-title":"Advances in nanomedicine-based retinal drug delivery: mechanisms and translational applications","volume":"24","author":"Nafar","year":"2025","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0485","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12034-022-02869-0","article-title":"Current perspectives in nanomedicine delivery for targeted ocular therapeutics","volume":"46","author":"Pardeshi","year":"2023","journal-title":"Bull Mater Sci"},{"issue":"3","key":"10.1016\/j.nano.2026.102965_bb0490","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s13346-020-00843-z","article-title":"Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives","volume":"11","author":"Gaballa","year":"2021","journal-title":"Drug Deliv Transl Res"},{"issue":"20","key":"10.1016\/j.nano.2026.102965_bb0495","doi-asserted-by":"crossref","first-page":"12102","DOI":"10.3390\/ijms232012102","article-title":"Lipid-based nanoparticulate systems for the ocular delivery of bioactives with anti-inflammatory properties","volume":"23","author":"Ana","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"23","key":"10.1016\/j.nano.2026.102965_bb0500","doi-asserted-by":"crossref","first-page":"11730","DOI":"10.3390\/ijms262311730","article-title":"Autoimmune diseases of the eyelid skin: molecular pathways, clinical manifestations, and therapeutic insights","volume":"26","author":"Lubo\u0144","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"24","key":"10.1016\/j.nano.2026.102965_bb0505","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.2174\/0929867325666181101110050","article-title":"Nanocarriers: a successful tool to increase solubility, stability and optimise bioefficacy of natural constituents","volume":"26","author":"Bilia","year":"2019","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.nano.2026.102965_bb0510","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.nano.2026.102965_bb0515","doi-asserted-by":"crossref","first-page":"123353","DOI":"10.1016\/j.biomaterials.2025.123353","article-title":"MicroRNA-loaded antioxidant nanoplatforms for prevention and treatment of experimental acute and chronic uveitis","author":"Sheng","year":"2025","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.nano.2026.102965_bb0520","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41433-020-0770-y","article-title":"Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases","volume":"34","author":"Seah","year":"2020","journal-title":"Eye"},{"key":"10.1016\/j.nano.2026.102965_bb0525","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jddst.2018.07.003","article-title":"Rational design of liposomes for sustained release drug delivery of bevacizumab to treat ocular angiogenesis","volume":"47","author":"Karumanchi","year":"2018","journal-title":"J Drug Delivery Sci Technol"},{"issue":"9","key":"10.1016\/j.nano.2026.102965_bb0530","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3390\/pharmaceutics14091931","article-title":"Ocular drug delivery: advancements and innovations","volume":"14","author":"Tian","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.102965_bb0535","doi-asserted-by":"crossref","first-page":"100218","DOI":"10.1016\/j.mtnano.2022.100218","article-title":"Nanoceria for ocular diseases: recent advances and future prospects","volume":"18","author":"Cui","year":"2022","journal-title":"Mater Today Nano"},{"issue":"6","key":"10.1016\/j.nano.2026.102965_bb0540","article-title":"Antioxidant properties of cerium oxide nanoparticles prevent retinal neovascular alterations in vitro and in vivo","volume":"11","author":"Tisi","year":"2022","journal-title":"Antioxidants (Basel)"},{"issue":"15","key":"10.1016\/j.nano.2026.102965_bb0545","doi-asserted-by":"crossref","first-page":"7467","DOI":"10.7150\/thno.112213","article-title":"Mn3O4 nanozyme-based anti-inflammatory therapy modulates microglial phenotype by downregulating TLR4\/NOX2 expression and further alleviates Alzheimer's disease pathology","volume":"15","author":"Xie","year":"2025","journal-title":"Theranostics"},{"issue":"15","key":"10.1016\/j.nano.2026.102965_bb0550","doi-asserted-by":"crossref","first-page":"7467","DOI":"10.7150\/thno.112213","article-title":"Mn3O4 nanozyme-based anti-inflammatory therapy modulates microglial phenotype by downregulating TLR4\/NOX2 expression and further alleviates Alzheimer's disease pathology","volume":"15","author":"Xie","year":"2025","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.nano.2026.102965_bb0555","doi-asserted-by":"crossref","first-page":"e2401309","DOI":"10.1002\/adhm.202401309","article-title":"Nanozymes for treating ocular diseases","volume":"14","author":"Wong","year":"2025","journal-title":"Adv Healthc Mater"},{"issue":"6","key":"10.1016\/j.nano.2026.102965_bb0560","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1089\/jop.2019.0105","article-title":"Ophthalmic applications of cerium oxide nanoparticles","volume":"36","author":"Maccarone","year":"2019","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.nano.2026.102965_bb0565","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jconrel.2019.01.018","article-title":"Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis","volume":"296","author":"Luo","year":"2019","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.nano.2026.102965_bb0570","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3390\/pr13030907","article-title":"Topical and transdermal delivery of nonsteroidal anti-inflammatory drugs (NSAIDs) for inflammation and pain: current trends and future directions in delivery systems","volume":"13","author":"Drosopoulou","year":"2025","journal-title":"Processes"},{"issue":"12","key":"10.1016\/j.nano.2026.102965_bb0575","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3390\/md15120370","article-title":"Chitosan nanoparticles as a mucoadhesive drug delivery system for ocular administration","volume":"15","author":"Silva","year":"2017","journal-title":"Mar Drugs"},{"issue":"4","key":"10.1016\/j.nano.2026.102965_bb0580","first-page":"48","article-title":"Topical drug delivery for posterior segment disease","volume":"5","author":"Kiernan","year":"2010","journal-title":"Ret Today"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11671-025-04234-6","article-title":"Ocular drug delivery systems based on nanotechnology: a comprehensive review for the treatment of eye diseases","volume":"20","author":"Bairagi","year":"2025","journal-title":"Discov Nano"},{"issue":"16","key":"10.1016\/j.nano.2026.102965_bb0590","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612976","article-title":"Biodegradable polymer-based drug-delivery systems for ocular diseases","volume":"24","author":"Tsung","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"17","key":"10.1016\/j.nano.2026.102965_bb0595","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176380","article-title":"Stimulus-responsive nanomedicines for disease diagnosis and treatment","volume":"21","author":"Liu","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0600","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/pharmaceutics13010108","article-title":"Ocular drug delivery to the retina: current innovations and future perspectives","volume":"13","author":"Kim","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.102965_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2022.103798","article-title":"The emerging role of 3D-printing in ocular drug delivery: challenges, current status, and future prospects","volume":"76","author":"Garg","year":"2022","journal-title":"J Drug Delivery Sci Technol"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0610","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10010028","article-title":"Ocular drug delivery barriers\u2014role of nanocarriers in the treatment of anterior segment ocular diseases","volume":"10","author":"Bachu","year":"2018","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.nano.2026.102965_bb0615","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/jop.2022.0144","article-title":"Intracameral drug delivery: a review of agents, indications, and outcomes","volume":"39","author":"Gautam","year":"2023","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0620","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1517\/17425247.1.1.99","article-title":"Periocular routes for retinal drug delivery","volume":"1","author":"Raghava","year":"2004","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0625","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/bioengineering9010041","article-title":"Targeting ocular drug delivery: an examination of local anatomy and current approaches","volume":"9","author":"Dosmar","year":"2022","journal-title":"Bioengineering"},{"key":"10.1016\/j.nano.2026.102965_bb0630","doi-asserted-by":"crossref","first-page":"105785","DOI":"10.1016\/j.jddst.2024.105785","article-title":"Insights into ocular therapeutics: a comprehensive review of anatomy, barriers, diseases and nanoscale formulations for targeted drug delivery","volume":"97","author":"Chandel","year":"2024","journal-title":"J Drug Delivery Sci Technol"},{"key":"10.1016\/j.nano.2026.102965_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115004","article-title":"Nanomaterial-based ophthalmic drug delivery","volume":"200","author":"Xie","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0640","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s11671-025-04234-6","article-title":"Ocular drug delivery systems based on nanotechnology: a comprehensive review for the treatment of eye diseases","volume":"20","author":"Bairagi","year":"2025","journal-title":"Discov Nano"},{"key":"10.1016\/j.nano.2026.102965_bb0645","doi-asserted-by":"crossref","first-page":"124192","DOI":"10.1016\/j.ijpharm.2024.124192","article-title":"Fostering the unleashing potential of nanocarriers-mediated delivery of ocular therapeutics","volume":"658","author":"Datta","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2026.102965_bb0650","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1039\/D5BM00325C","article-title":"Nanomedicine in ophthalmology: conquering anatomical barriers and enhancing therapeutic efficacy","volume":"14","author":"Wang","year":"2025","journal-title":"Biomater Sci"},{"issue":"12","key":"10.1016\/j.nano.2026.102965_bb0655","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00210-022-02287-3","article-title":"Nanomedicine and drug delivery to the retina: current status and implications for gene therapy","volume":"395","author":"Tawfik","year":"2022","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"issue":"12","key":"10.1016\/j.nano.2026.102965_bb0660","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3390\/pharmaceutics12121215","article-title":"Three-dimensional human cell culture models to study the pathophysiology of the anterior eye","volume":"12","author":"Garc\u00eda-Posadas","year":"2020","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0665","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1186\/s12951-024-02930-6","article-title":"Intestinal nanoparticle delivery and cellular response: a review of the bidirectional nanoparticle-cell interplay in mucosa based on physiochemical properties","volume":"22","author":"Wang","year":"2024","journal-title":"J Nanobiotechnol"},{"issue":"24","key":"10.1016\/j.nano.2026.102965_bb0670","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.3390\/jcm13247651","article-title":"Nanomedicine in ophthalmology: from bench to bedside","volume":"13","author":"Mahaling","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.nano.2026.102965_bb0675","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.2147\/IJN.S329831","article-title":"Ten years of knowledge of nano-carrier based drug delivery systems in ophthalmology: current evidence, challenges, and future prospective","author":"Zhang","year":"2021","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0680","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12951-020-00745-9","article-title":"Distribution of polymeric nanoparticles in the eye: implications in ocular disease therapy","volume":"19","author":"Swetledge","year":"2021","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0685","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/s12951-022-01658-5","article-title":"Immune modulating nanoparticles for the treatment of ocular diseases","volume":"20","author":"Fang","year":"2022","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.nano.2026.102965_bb0690","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2147\/IJN.S446425","article-title":"Topical ophthalmic liposomes dual-modified with penetratin and hyaluronic acid for the noninvasive treatment of neovascular age-related macular degeneration","author":"Sun","year":"2024","journal-title":"Int J Nanomedicine"},{"issue":"4","key":"10.1016\/j.nano.2026.102965_bb0695","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s13346-020-00733-4","article-title":"Atorvastatin-loaded solid lipid nanoparticles as eye drops: proposed treatment option for age-related macular degeneration (AMD)","volume":"10","author":"Yadav","year":"2020","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.nano.2026.102965_bb0700","doi-asserted-by":"crossref","first-page":"118811","DOI":"10.1016\/j.ijpharm.2019.118811","article-title":"Establishment of a multilayered 3D cellular model of the retinal-blood barrier","volume":"572","author":"Oliveira","year":"2019","journal-title":"Int J Pharm"},{"issue":"15","key":"10.1016\/j.nano.2026.102965_bb0705","doi-asserted-by":"crossref","first-page":"12046","DOI":"10.3390\/ijms241512046","article-title":"Three-dimensional cell cultures: the bridge between in vitro and in vivo models","volume":"24","author":"Urz\u00ec","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.nano.2026.102965_bb0710","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4103\/0301-4738.156914","article-title":"Experimental autoimmune uveitis and other animal models of uveitis: an update","volume":"63","author":"Bansal","year":"2015","journal-title":"Indian J Ophthalmol"},{"issue":"2","key":"10.1016\/j.nano.2026.102965_bb0715","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.aopr.2024.11.003","article-title":"Nano-based drug delivery systems for the treatment of non-infectious uveitis","volume":"5","author":"Wu","year":"2025","journal-title":"Adv Ophthalmol Pract Res"},{"issue":"9","key":"10.1016\/j.nano.2026.102965_bb0720","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1021\/acs.molpharmaceut.6b00445","article-title":"Prolonged ocular retention of mucoadhesive nanoparticle eye drop formulation enables treatment of eye diseases using significantly reduced dosage","volume":"13","author":"Liu","year":"2016","journal-title":"Mol Pharm"},{"issue":"23","key":"10.1016\/j.nano.2026.102965_bb0725","doi-asserted-by":"crossref","first-page":"16661","DOI":"10.3390\/ijms242316661","article-title":"Animal models in eye research: focus on corneal pathologies","volume":"24","author":"Loiseau","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.nano.2026.102965_bb0730","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/17425247.2018.1420053","article-title":"Nanomedicine for immunosuppressive therapy: achievements in pre-clinical and clinical research","volume":"15","author":"Al-Lawati","year":"2018","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.nano.2026.102965_bb0735","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejpb.2017.03.006","article-title":"Cyclosporine A delivery to the eye: a comprehensive review of academic and industrial efforts","volume":"117","author":"Lallemand","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"10.1016\/j.nano.2026.102965_bb0740","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1080\/09273948.2024.2423869","article-title":"Review on the use of difluprednate in inflammatory eye disorders: the topical steroid that goes the distance","volume":"33","author":"Amer","year":"2025","journal-title":"Ocul Immunol Inflamm"},{"issue":"7","key":"10.1016\/j.nano.2026.102965_bb0745","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1021\/acsabm.4c00316","article-title":"A physiochemical, in vitro, and in vivo comparative analysis of verteporfin\u2013lipid conjugate formulations: solid lipid nanoparticles and liposomes","volume":"7","author":"Shah","year":"2024","journal-title":"ACS Appl Bio Mater"},{"key":"10.1016\/j.nano.2026.102965_bb0750","first-page":"381","article-title":"The role of difluprednate ophthalmic emulsion in clinical practice","author":"Jamal","year":"2009","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.nano.2026.102965_bb0755","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2147\/OPTH.S113437","article-title":"Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature","author":"Rhee","year":"2017","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0760","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12348-019-0168-9","article-title":"Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema","volume":"9","author":"Weber","year":"2019","journal-title":"J Ophthalmol Inflamm Infect"},{"issue":"7","key":"10.1016\/j.nano.2026.102965_bb0765","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.3390\/biomedicines11071901","article-title":"The evolution of triamcinolone acetonide therapeutic use in retinal diseases: from off-label intravitreal injection to advanced nano-drug delivery systems","volume":"11","author":"Aceves-Franco","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.nano.2026.102965_bb0770","doi-asserted-by":"crossref","DOI":"10.4137\/OED.S7791","article-title":"Review of azithromycin ophthalmic 1% solution (AzaSite\u00ae) for the treatment of ocular infections","volume":"4","author":"Opitz","year":"2012","journal-title":"Ophthalmol Eye Dis"},{"key":"10.1016\/j.nano.2026.102965_bb0775","doi-asserted-by":"crossref","DOI":"10.4137\/OED.S4102","article-title":"Besifloxacin ophthalmic suspension: emerging evidence of its therapeutic value in bacterial conjunctivitis","volume":"3","author":"Khimdas","year":"2011","journal-title":"Ophthalmol Eye Dis"},{"key":"10.1016\/j.nano.2026.102965_bb0780","doi-asserted-by":"crossref","first-page":"121515","DOI":"10.1016\/j.ijpharm.2022.121515","article-title":"Topical pharmacokinetics of dexamethasone suspensions in the rabbit eye: bioavailability comparison","volume":"615","author":"Naageshwaran","year":"2022","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0785","doi-asserted-by":"crossref","first-page":"1336043","DOI":"10.1080\/20016689.2017.1336043","volume":"5","author":"Eroglu","year":"2017","journal-title":"Journal of Market Access & Health Policy"},{"key":"10.1016\/j.nano.2026.102965_bb0790","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2147\/OPTH.S208700","article-title":"Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies","author":"Schechter","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.nano.2026.102965_bb0795","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2147\/OPTH.S228070","article-title":"A review of topical cyclosporine a formulations\u2014a disease-modifying agent for keratoconjunctivitis sicca","author":"Jerkins","year":"2020","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0800","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2217\/pmt-2021-0023","article-title":"KPI-121 1% for pain and inflammation in ocular surgery","volume":"12","author":"Beckman","year":"2022","journal-title":"Pain Manag"},{"key":"10.1016\/j.nano.2026.102965_bb0805","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2147\/OPTH.S367756","article-title":"Open-label extension study comparing latanoprost 0.005% without vs with benzalkonium chloride in open-angle glaucoma or ocular hypertension","volume":"16","author":"Lee","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.nano.2026.102965_bb0810","article-title":"The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares","volume":"13","author":"Gupta","year":"2021","journal-title":"Ther Adv Ophthalmol"},{"key":"10.1016\/j.nano.2026.102965_bb0815","series-title":"A Phase II, Double-masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease","year":"2014"},{"key":"10.1016\/j.nano.2026.102965_bb0820","series-title":"A Multicenter, Randomized, Double-masked, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of APP13007 for the Treatment of Inflammation and Pain After Cataract Surgery, Including a Corneal Endothelial Cell Sub-study","year":"2021"},{"key":"10.1016\/j.nano.2026.102965_bb0825","series-title":"A Phase 3 Randomized, Placebo-controlled, Double-masked, Multicenter, Safety and Efficacy Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-host Disease","year":"2018"},{"key":"10.1016\/j.nano.2026.102965_bb0830","series-title":"Safety and Efficacy of KPI-121 1% Ophthalmic Suspension Versus Prednisolone Acetate Ophthalmic Suspension 1% for the Treatment of Inflammation Following Cataract Surgery in Children 0 to 3 Years of Age","year":"2018"},{"key":"10.1016\/j.nano.2026.102965_bb0835","series-title":"A Randomized, Double-masked, Vehicle-controlled Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle in the Treatment of Inflammation and Pain Following Cataract Surgery","year":"2021"},{"key":"10.1016\/j.nano.2026.102965_bb0840","series-title":"A Randomized, Double-masked, Dose-ranging Study to Evaluate the Safety and Tolerability of TRS01 Eye Drops in Participants with Active Non-infectious Anterior Uveitis","year":"2020"},{"key":"10.1016\/j.nano.2026.102965_bb0845","series-title":"A Multicenter, Active Control, Parallel Group, Randomized, Double-blind, Phase II Clinical Trial to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops in Patients With Dry Eye Disease","year":"2023"},{"issue":"46","key":"10.1016\/j.nano.2026.102965_bb0850","doi-asserted-by":"crossref","first-page":"27835","DOI":"10.1039\/D0RA04971A","article-title":"Nanocarriers for ocular drug delivery: current status and translational opportunity","volume":"10","author":"Gorantla","year":"2020","journal-title":"RSC Adv"},{"key":"10.1016\/j.nano.2026.102965_bb0855","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2024.1421959","article-title":"Lipid-based nanoparticles: innovations in ocular drug delivery","volume":"11","author":"Baig","year":"2024","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.nano.2026.102965_bb0860","doi-asserted-by":"crossref","first-page":"2502315","DOI":"10.1002\/smll.202502315","article-title":"Nanoparticle therapeutics in clinical perspective: classification, marketed products, and regulatory landscape","author":"Desai","year":"2025","journal-title":"Small"},{"issue":"5","key":"10.1016\/j.nano.2026.102965_bb0865","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17050599","article-title":"Ocular drug delivery: emerging approaches and advances","volume":"17","author":"Gade","year":"2025","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.nano.2026.102965_bb0870","doi-asserted-by":"crossref","first-page":"6029","DOI":"10.1097\/MS9.0000000000001399","article-title":"Drug delivery methods based on nanotechnology for the treatment of eye diseases","volume":"85","author":"Khaled","year":"2023","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.nano.2026.102965_bb0875","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.colsurfb.2017.07.038","article-title":"Recent applications of PLGA based nanostructures in drug delivery","volume":"159","author":"Mir","year":"2017","journal-title":"Colloids Surf B: Biointerfaces"},{"key":"10.1016\/j.nano.2026.102965_bb0880","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijpharm.2019.03.011","article-title":"Natural biodegradable polymers based nano-formulations for drug delivery: a review","volume":"561","author":"George","year":"2019","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.nano.2026.102965_bb0885","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1208\/s12249-023-02516-9","article-title":"Ocular drug delivery: a comprehensive review","volume":"24","author":"Ahmed","year":"2023","journal-title":"AAPS PharmSciTech"},{"issue":"16","key":"10.1016\/j.nano.2026.102965_bb0890","doi-asserted-by":"crossref","first-page":"1802289","DOI":"10.1002\/advs.201802289","article-title":"Safety assessment of nanomaterials to eyes: an important but neglected issue","volume":"6","author":"Zhu","year":"2019","journal-title":"Adv Sci"},{"key":"10.1016\/j.nano.2026.102965_bb0895","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jconrel.2019.06.040","article-title":"Translation of nanomedicines from lab to industrial scale synthesis: the case of squalene-adenosine nanoparticles","volume":"307","author":"Dormont","year":"2019","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0900","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3390\/pharmaceutics14010106","article-title":"Development of pharmaceutical nanomedicines: from the bench to the market","volume":"14","author":"Halwani","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.102965_bb0905","series-title":"Multifunctional Nanocarriers","first-page":"501","article-title":"Current status of FDA-approved marketed nano drug products: regulatory considerations","author":"Banala","year":"2022"},{"issue":"7","key":"10.1016\/j.nano.2026.102965_bb0910","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.oret.2022.03.018","article-title":"The promise and perils of biosimilars in ophthalmology","volume":"6","author":"Williams","year":"2022","journal-title":"Ophthalmol Ret"},{"issue":"2","key":"10.1016\/j.nano.2026.102965_bb0915","doi-asserted-by":"crossref","first-page":"163","DOI":"10.30574\/gscbps.2024.29.2.0422","article-title":"Innovative ocular drug delivery systems: a comprehensive review of nano formulations and future directions","volume":"29","author":"Harshdeep","year":"2024","journal-title":"GSC Biol Pharm Sci"},{"issue":"6","key":"10.1016\/j.nano.2026.102965_bb0920","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/17469899.2022.2152005","article-title":"Emerging biosimilars for retinal diseases","volume":"17","author":"Sharma","year":"2022","journal-title":"Exp Rev Ophthalmol"},{"issue":"23","key":"10.1016\/j.nano.2026.102965_bb0925","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1080\/17435889.2025.2571060","article-title":"Silver nanoparticles: a new frontier in ophthalmic innovation and treatment","volume":"20","author":"Wang","year":"2025","journal-title":"Nanomedicine"},{"issue":"12","key":"10.1016\/j.nano.2026.102965_bb0930","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/IAE.0000000000003626","article-title":"Anti-vascular endothelial growth factor biosimilars in ophthalmology","volume":"42","author":"Kaiser","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.nano.2026.102965_bb0935","series-title":"1ISG-010 the Cost of Lacking Regulatory Clarity for Nanosimilars","author":"Fl\u00fchmann","year":"2018"},{"key":"10.1016\/j.nano.2026.102965_bb0940","series-title":"Regulatory Requirements of Biosimilars: Drug Development in Ophthalmology, Part 1","first-page":"550","author":"Rowe-Rendleman","year":"2024"},{"issue":"3","key":"10.1016\/j.nano.2026.102965_bb0945","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers"},{"issue":"13","key":"10.1016\/j.nano.2026.102965_bb0950","doi-asserted-by":"crossref","first-page":"1701400","DOI":"10.1002\/adhm.201701400","article-title":"Recent advances in the development of antimicrobial nanoparticles for combating resistant pathogens","volume":"7","author":"Lakshminarayanan","year":"2018","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0955","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/732340","article-title":"Dendrimeric systems and their applications in ocular drug delivery","volume":"2013","author":"Yavuz","year":"2013","journal-title":"Sci World J"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0960","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/ijms22010385","article-title":"Safe nanoparticles: are we there yet?","volume":"22","author":"Najahi-Missaoui","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nano.2026.102965_bb0965","series-title":"Surface Coatings: General Issues for Consideration Regarding Parental Administration of Coated Nanomedicine Products","author":"European Medicines Agency","year":"2013"},{"issue":"4","key":"10.1016\/j.nano.2026.102965_bb0970","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1208\/s12248-019-0329-7","article-title":"Report of the AAPS guidance forum on the FDA draft guidance for industry:\u201cdrug products, including biological products, that contain nanomaterials\u201d","volume":"21","author":"de Vlieger","year":"2019","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0975","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","article-title":"Biodegradable polymeric nanoparticles based drug delivery systems","volume":"75","author":"Kumari","year":"2010","journal-title":"Colloids Surf B: Biointerfaces"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0980","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1556-276X-8-102","article-title":"Liposome: classification, preparation, and applications","volume":"8","author":"Akbarzadeh","year":"2013","journal-title":"Nanoscale Res Lett"},{"key":"10.1016\/j.nano.2026.102965_bb0985","doi-asserted-by":"crossref","first-page":"113992","DOI":"10.1016\/j.jconrel.2025.113992","article-title":"Innovative solid lipid nanoparticle formulations for ocular therapeutics and related patents: a systematic review","author":"Ahmed","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2026.102965_bb0990","doi-asserted-by":"crossref","first-page":"931759","DOI":"10.3389\/fmolb.2022.931759","article-title":"Nanoparticles in ocular applications and their potential toxicity","volume":"9","author":"Yang","year":"2022","journal-title":"Front Mol Biosci"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb0995","doi-asserted-by":"crossref","first-page":"19606","DOI":"10.1038\/s41598-025-03804-z","article-title":"Toxicity analysis of gold nanoparticle formulations used for intraocular applications","volume":"15","author":"Hajrasouliha","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.nano.2026.102965_bb1000","doi-asserted-by":"crossref","first-page":"102163","DOI":"10.1016\/j.nantod.2024.102163","article-title":"Anti-PEG antibodies: current situation and countermeasures","volume":"55","author":"Fu","year":"2024","journal-title":"Nano Today"},{"issue":"2","key":"10.1016\/j.nano.2026.102965_bb1005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5497\/wjp.v2.i2.47","article-title":"Ocular drug delivery systems: an overview","volume":"2","author":"Patel","year":"2013","journal-title":"World J Pharmacol"},{"issue":"7","key":"10.1016\/j.nano.2026.102965_bb1010","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/17425247.2018.1496080","article-title":"Recent advance of nanoparticle-based topical drug delivery to the posterior segment of the eye","volume":"15","author":"Wang","year":"2018","journal-title":"Expert Opin Drug Deliv"},{"issue":"5\u20136","key":"10.1016\/j.nano.2026.102965_bb1015","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.drudis.2010.12.004","article-title":"Drug delivery to the posterior segment of the eye","volume":"16","author":"Thrimawithana","year":"2011","journal-title":"Drug Discov Today"},{"issue":"2","key":"10.1016\/j.nano.2026.102965_bb1020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2004.07.001","article-title":"Model of transient drug diffusion across cornea","volume":"99","author":"Zhang","year":"2004","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2026.102965_bb1025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.addr.2018.01.007","article-title":"Microspheres as intraocular therapeutic tools in chronic diseases of the optic nerve and retina","volume":"126","author":"Bravo-Osuna","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"10.1016\/j.nano.2026.102965_bb1030","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye (Lond)"},{"issue":"3","key":"10.1016\/j.nano.2026.102965_bb1035","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2174\/1567202614666170619081929","article-title":"Triamcinolone acetonide suppresses inflammation and facilitates vascular barrier function in human retinal microvascular endothelial cells","volume":"14","author":"Imai","year":"2017","journal-title":"Curr Neurovasc Res"},{"key":"10.1016\/j.nano.2026.102965_bb1040","series-title":"Ocular Drug Delivery: A Clue from Nanotechnology","first-page":"188","author":"Bucolo","year":"2012"},{"issue":"11","key":"10.1016\/j.nano.2026.102965_bb1045","doi-asserted-by":"crossref","first-page":"12357","DOI":"10.1021\/acsnano.9b04857","article-title":"Reshaping prostate tumor microenvironment to suppress metastasis via cancer-associated fibroblast inactivation with peptide-assembly-based nanosystem","volume":"13","author":"Lang","year":"2019","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb1050","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1021\/acsnano.8b05408","article-title":"Nanoscale bupivacaine formulations to enhance the duration and safety of intravenous regional anesthesia","volume":"13","author":"Weldon","year":"2018","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.nano.2026.102965_bb1055","first-page":"390","article-title":"Nanoparticles in the ocular drug delivery","volume":"6","author":"Zhou","year":"2013","journal-title":"Int J Ophthalmol"},{"issue":"11","key":"10.1016\/j.nano.2026.102965_bb1060","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1021\/mp3002733","article-title":"RGD-based strategies to target alpha (v) beta (3) integrin in cancer therapy and diagnosis","volume":"9","author":"Danhier","year":"2012","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.nano.2026.102965_bb1065","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ddr.20265","article-title":"Integrin \u03b1v\u03b23-targeted cancer therapy","volume":"69","author":"Liu","year":"2008","journal-title":"Drug Dev Res"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb1070","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/jbm.a.33233","article-title":"Functionalization of reactive polymer multilayers with RGD and an antifouling motif: RGD density provides control over human corneal epithelial cell\u2013substrate interactions","volume":"100","author":"Tocce","year":"2012","journal-title":"J Biomed Mater Res A"},{"issue":"38","key":"10.1016\/j.nano.2026.102965_bb1075","doi-asserted-by":"crossref","first-page":"16157","DOI":"10.1073\/pnas.0908201106","article-title":"C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration","volume":"106","author":"Teesalu","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.nano.2026.102965_bb1080","first-page":"609","article-title":"Conjugation of cell-penetrating peptides with poly (lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery","author":"Vasconcelos","year":"2015","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2026.102965_bb1085","doi-asserted-by":"crossref","first-page":"1544393","DOI":"10.3389\/fmed.2025.1544393","article-title":"Regulatory pathways and guidelines for nanotechnology-enabled health products: a comparative review of EU and US frameworks","volume":"12","author":"Rodr\u00edguez-G\u00f3mez","year":"2025","journal-title":"Front Med"},{"issue":"12","key":"10.1016\/j.nano.2026.102965_bb1090","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16121521","article-title":"Effect of lipid nanoparticle physico-chemical properties and composition on their interaction with the immune system","volume":"16","author":"Catenacci","year":"2024","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.nano.2026.102965_bb1095","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.2217\/nnm-2018-0040","article-title":"Factors relating to the biodistribution & clearance of nanoparticles & their effects on in vivo application","volume":"13","author":"Wei","year":"2018","journal-title":"Nanomedicine"},{"issue":"4","key":"10.1016\/j.nano.2026.102965_bb1100","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1021\/acs.chemrev.5b00346","article-title":"Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release","volume":"116","author":"Kamaly","year":"2016","journal-title":"Chem Rev"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb1105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nano.2010.11.002","article-title":"Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes","volume":"7","author":"Vizirianakis","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.nano.2026.102965_bb1110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2025.107120","article-title":"Progress on drug nanoparticle manufacturing: exploring the adaptability of batch bottom-up approaches to continuous manufacturing","volume":"111","author":"Costa","year":"2025","journal-title":"J Drug Delivery Sci Technol"},{"issue":"10","key":"10.1016\/j.nano.2026.102965_bb1115","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1080\/17425247.2016.1193151","article-title":"Microfluidic nanoprecipitation systems for preparing pure drug or polymeric drug loaded nanoparticles: an overview","volume":"13","author":"Ding","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb1120","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3390\/pharmaceutics14010134","article-title":"Topical drug delivery to the posterior segment of the eye","volume":"14","author":"L\u00f6scher","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb1125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s44301-025-00008-2","article-title":"Nanotechnology in medicine: a double-edged sword for health outcomes","volume":"1","author":"Fortune","year":"2025","journal-title":"Health Nanotechnol"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb1130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2217\/17435889.2.1.11","article-title":"Ocular drug delivery: nanomedicine applications","volume":"2","author":"Vandervoort","year":"2007","journal-title":"Nanomedicine"},{"issue":"3","key":"10.1016\/j.nano.2026.102965_bb1135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40123-020-00257-7","article-title":"Therapies based on nanoparticles for eye drug delivery","volume":"9","author":"Meza-Rios","year":"2020","journal-title":"Ophthalmol Therapy"},{"issue":"10","key":"10.1016\/j.nano.2026.102965_bb1140","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1021\/acs.jproteome.5c00208","article-title":"Quantifying hydrolytic enzymes in the vitreous humor of humans and nonhuman species using targeted proteomics","volume":"24","author":"Ruttenberg","year":"2025","journal-title":"J Proteome Res"},{"issue":"4","key":"10.1016\/j.nano.2026.102965_bb1145","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2174\/2211738510666220806102612","article-title":"Targeted nanotherapies for the posterior segment of the eye: an integrative review on recent advancements and challenges","volume":"10","author":"Gogoi","year":"2022","journal-title":"Pharm Nanotechnol"},{"issue":"186","key":"10.1016\/j.nano.2026.102965_bb1150","doi-asserted-by":"crossref","first-page":"20210734","DOI":"10.1098\/rsif.2021.0734","article-title":"Application of an organotypic ocular perfusion model to assess intravitreal drug distribution in human and animal eyes","volume":"19","author":"Chan","year":"2022","journal-title":"J R Soc Interface"},{"issue":"2","key":"10.1016\/j.nano.2026.102965_bb1155","doi-asserted-by":"crossref","first-page":"152317","DOI":"10.1016\/j.imbio.2022.152317","article-title":"Nanoparticle-induced immune response: health risk versus treatment opportunity?","volume":"228","author":"Pondman","year":"2023","journal-title":"Immunobiology"},{"key":"10.1016\/j.nano.2026.102965_bb1160","doi-asserted-by":"crossref","first-page":"118997","DOI":"10.1016\/j.ecoenv.2025.118997","article-title":"Ocular toxicity and potential mechanism of nanomaterials: an issue worthy of investigation","volume":"303","author":"Xie","year":"2025","journal-title":"Ecotoxicol Environ Saf"},{"key":"10.1016\/j.nano.2026.102965_bb1165","doi-asserted-by":"crossref","first-page":"125202","DOI":"10.1016\/j.ijpharm.2025.125202","article-title":"Navigating translational research in nanomedicine: a strategic guide to formulation and manufacturing","author":"Zhang","year":"2025","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.nano.2026.102965_bb1170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-5956-11-22","article-title":"In-depth mass spectrometric mapping of the human vitreous proteome","volume":"11","author":"Aretz","year":"2013","journal-title":"Proteome Sci"},{"key":"10.1016\/j.nano.2026.102965_bb1175","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.exer.2015.05.003","article-title":"Rabbit as an animal model for intravitreal pharmacokinetics: clinical predictability and quality of the published data","volume":"137","author":"Del Amo","year":"2015","journal-title":"Exp Eye Res"},{"issue":"10","key":"10.1016\/j.nano.2026.102965_bb1180","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1021\/acs.molpharmaceut.9b00679","article-title":"Intravitreal pharmacokinetics in mice: SPECT\/CT imaging and scaling to rabbits and humans","volume":"16","author":"Schmitt","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nano.2026.102965_bb1185","doi-asserted-by":"crossref","first-page":"109638","DOI":"10.1016\/j.exer.2023.109638","article-title":"Quantitative intravitreal pharmacokinetics in mouse as a step towards inter-species translation","volume":"235","author":"Puranen","year":"2023","journal-title":"Exp Eye Res"},{"issue":"11","key":"10.1016\/j.nano.2026.102965_bb1190","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s11095-020-02946-1","article-title":"Extended pharmacokinetic model of the intravitreal injections of macromolecules in rabbits. Part 2: parameter estimation based on concentration dynamics in the vitreous, retina, and aqueous humor: Lamminsalo et al","volume":"37","author":"Lamminsalo","year":"2020","journal-title":"Pharm Res"},{"issue":"1\u20132","key":"10.1016\/j.nano.2026.102965_bb1195","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ijpharm.2018.07.070","article-title":"Diffusion through the ex vivo vitreal body\u2013bovine, porcine, and ovine models are poor surrogates for the human vitreous","volume":"550","author":"Shafaie","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2026.102965_bb1200","first-page":"101092","article-title":"Critical quality attributes of lipid nanoparticles and in vivo fate","author":"Di","year":"2025","journal-title":"Asian J Pharm Sci"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963426000663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963426000663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T07:27:36Z","timestamp":1784014056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963426000663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":240,"alternative-id":["S1549963426000663"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2026.102965","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in nanomedicine for ocular inflammatory diseases","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2026.102965","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102965"}}